Results 91 to 100 of about 121,431 (264)

SOX5 Orchestrates Malignant Evolution via Promoter‐Centric Chromatin Remodeling in MYC‐Driven B‐Cell Lymphoma

Advanced Science, EarlyView.
In MYC‐enforced B‐cell lymphoma, SOX5 occupies promoter‐proximal regulatory regions and is associated with reduced chromatin accessibility at the PCNP locus. PCNP repression promotes proliferative remodeling by limiting apoptosis and cell‐cycle restraint.
Yiyou Mao, Zhenyuan Jia, Xiao‐Qin Mu, Ruilin Wang, Jianli Ma, Qingyuan Zhang, Yuwei Deng   +6 more
wiley   +1 more source

Application progress on immunotherapy with chimeric antigen receptor T cell in patients with hematological malignancies

Huli yanjiu, 2020
Reviewing application progress on immunotherapy with chimeric antigen receptor T cell（CAR⁃T） in patients with hematological malignancies from 4 aspects,such as collection,pretreatment,note on cell reinfusion,and treatment complication of chimeric antigen
MENG Rui, XU Li, WAN Ying
doaj  

Programmable Nanobody‐Targeting Chimeras Enable Intracellular Viral Protein Degradation

Advanced Science, EarlyView.
Nab‐TAC enables targeted degradation of HBV surface antigen (HBsAg) in vivo. By fusing nanobody‐based recognition domains with programmable proteasome‐recruiting degradation signals, Nab‐TAC reduces HBsAg levels in a hydrodynamic HBV mouse model. ABSTRACT Chronic hepatitis B virus (HBV) infection remains a major global health challenge, largely because
Max Yu‐Chen Pan, Ting‐Hui Lee, Tzu‐Ning Peng, Eva Yi‐Hsuan Wu, Yu‐Ting Chiu, Chih‐Chien Chiu, Hong Vinh Nguyen, Yuan‐Shao Pao, Ming‐Hong Chao, Richard Kuan‐Lin Lee, Han‐Chung Wu, Lily Hui‐Ching Wang   +11 more
wiley   +1 more source

Chronic HBV Infection Disrupts CCL5‐Secreting cNK Cells and Attenuates Liver Accumulation and Activation of DCs and HBV‐Specific T Cells

Advanced Science, EarlyView.
ADORA2A activation suppresses NFκB‐dependent CCL5 production in cNK cells during chronic HBV infection, disrupting intrahepatic DC recruitment and HBV‐specific CD8+ T‐cell differentiation and function. Targeting the ADORA2A/NFκB/CCL5 axis restores antiviral immunity and facilitates HBV clearance.
Ailu Yang, Yucan Wang, Yating Yu, Jing Wu, Cuiping Bao, Zixuan Wang, Qiuju Han, Zhigang Tian, Jian Zhang, Huajun Zhao   +9 more
wiley   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

Review of the Molecular and Developmental Basis of Myhre Syndrome, Bench Research

American Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT Myhre syndrome (MS) is a connective‐tissue disorder within the acromelic dysplasia spectrum. It is characterized by congenital craniofacial, skeletal, cutaneous anomalies, respiratory, cardiovascular along with intellectual disability, deafness, and progressive fibrosis.
Camille Viaut, Valerie Cormier‐Daire
wiley   +1 more source

Effectors of the Future: Universal Chimeric Antigen Receptor

Transfusion Medicine and Hemotherapy
<b><i>Background:</i></b> Cellular therapies leveraging genetically engineered immune effector cells have witnessed a remarkable surge in success, particularly evident in the notable high rates of remission induction and durable remissions observed in a substantial proportion of heavily pretreated patients with refractory B ...
Schlegel, Lara Sophie, Schlegel, Patrick
openaire   +2 more sources

Humanized immune system animal models and their recent applications

Animal Models and Experimental Medicine, EarlyView.
In this review, we provide an updated and comprehensive overview of the current state of humanized immune system animal model research. We discuss the variety of techniques used to produce humanized mice with their respective strengths and weaknesses, and evaluate the advantages and limitations of these models, including issues with incomplete immune ...
Nicolas Skuli, Rudra B. Amin, A’ishah Bakayoko, Marisa Kruidenier, Sahara Aqui, Sarah J. Skuli, Terence P. Gade   +6 more
wiley   +1 more source

Recent advances in adoptive cell therapy for cancer immunotherapy

Frontiers in Immunology
Adoptive cell therapy (ACT), a key direction in tumor immunotherapy, has achieved remarkable progress in recent years. This paper systematically reviews the current status and future trends of ACT, covering lymphokine-activated killer cells (LAK), tumor ...
Jiameng Qian, Jiameng Qian, Yuhua Liu, Yuhua Liu   +3 more
doaj   +1 more source

Engraftment of sheep splenic lymphocytes into NBSGW mice and application in Brucella infection

Animal Models and Experimental Medicine, EarlyView.
A sheep splenocyte‐reconstituted mouse model (Sh‐Spl mice) was established via intravenous injection of sheep splenic lymphocytes into immunodeficient mice to evaluate Brucella infection. Abstract Background The development of immune reconstituted xenograft mouse models has addressed the limitations imposed by interspecies immunological differences in ...
Xiaowei Wang, Shicheng Wan, Yanmin Guo, Hongyu Han, Fei Luo, Dongmei Jiang, Xiaorong Yang, Quanhai Pang, Haisheng Yu, Jinlian Hua   +9 more
wiley   +1 more source